Evidence map›Paper›PMID 42638726›Full record

ArticleFrontiers in tuberculosis2023

Acute phase proteins and IP-10 in plasma for tuberculosis diagnosis.

Bárbara Molina-Moya, Raquel Villar-Hernández, Nelly Ciobanu, Beatriz Muriel-Moreno, Alicia Lacoma, Alexandru Codreanu, Irene Latorre, Daria Smalchuk, Cristina Prat-Aymerich, Valeriu Crudu and 3 more

Abstract read
In one paragraph

Article in Frontiers in tuberculosis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Bárbara Molina-Moya *Institut d'Investigació Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, CIBER de Enfermedades Respiratorias (CIBERES), Universitat Autònoma de Barcelona, Barcelona, Spain.
Raquel Villar-Hernández *Institut d'Investigació Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, CIBER de Enfermedades Respiratorias (CIBERES), Universitat Autònoma de Barcelona, Barcelona, Spain.
Nelly Ciobanu *Institutia Medico-Sanitara Publica, Institutul de Ftiziopneumologie "Chiril Draganiuc", Chişinău, Moldova.
Beatriz Muriel-Moreno *Institut d'Investigació Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, CIBER de Enfermedades Respiratorias (CIBERES), Universitat Autònoma de Barcelona, Barcelona, Spain.
Alicia LacomaInstitut d'Investigació Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, CIBER de Enfermedades Respiratorias (CIBERES), Universitat Autònoma de Barcelona, Barcelona, Spain.
Alexandru CodreanuInstitutia Medico-Sanitara Publica, Institutul de Ftiziopneumologie "Chiril Draganiuc", Chişinău, Moldova.
Irene LatorreInstitut d'Investigació Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, CIBER de Enfermedades Respiratorias (CIBERES), Universitat Autònoma de Barcelona, Barcelona, Spain.
Daria SmalchukInstitut d'Investigació Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, CIBER de Enfermedades Respiratorias (CIBERES), Universitat Autònoma de Barcelona, Barcelona, Spain.
Cristina Prat-Aymerich *Institut d'Investigació Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, CIBER de Enfermedades Respiratorias (CIBERES), Universitat Autònoma de Barcelona, Barcelona, Spain.
Valeriu CruduInstitutia Medico-Sanitara Publica, Institutul de Ftiziopneumologie "Chiril Draganiuc", Chişinău, Moldova.
Konstantina KontogianniCentre for Drugs and Diagnostics, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Luis E CuevasCentre for Drugs and Diagnostics, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
José DomínguezInstitut d'Investigació Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, CIBER de Enfermedades Respiratorias (CIBERES), Universitat Autònoma de Barcelona, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tuberculosis (TB) is a leading cause of death from a single infectious agent, and triage tests based on biomarkers may help to improve the diagnosis. This study aims to determine whether C-reactive protein (CRP), interferon-γ-inducible protein 10 (IP-10), α1-acid glycoprotein (AGP), and α1-anti-trypsin (AAT) could be useful for a screening test in patients with presumptive TB disease. Methods: CRP, IP-10, AGP, and AAT were measured in plasma samples from 277 patients with presumptive TB disease in the Republic of Moldova in a prospective study. Results: In general, the levels of all the biomarkers were higher in patients with TB than in the other groups ( Conclusion: The levels of the tested biomarkers were different throughout the patient groups studied, but their suboptimal diagnostic performance either as individual biomarkers or in combination does not favor their use for triage testing.

Indexed as

C-reactive proteinIP-10triageα1-acid glycoproteinα1-antitrypsin

Identifiers

PMID42638726
PMCPMC13494927

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.